Bora Group announce the rebranding of Yuta Health to Bora Health

March 25, 2022

<p>TAIPEI, July 6, 2021 /PRNewswire/ -- Leading Taiwan-based contract development and manufacturing organization (CDMO) Bora Group today announced a name change for its subsidiary, currently Yuta Health, to Bora Health Inc. as part of an overall plan to integrate its distribution operations and brands. With the name change, Bora plans to complete the merging of the operations of Bora Health and Union Pharmaceutical by the end of 2021. In the future, Bora's two main businesses, CDMO and distribution services, will integrate brand resources and focus on the global development of their respective manufacturing and sales businesses in order to create greater value and benefits.<br />Bora's executives have reiterated that the group remains committed to driving the success of its pharmaceutical customers in the global market. This will be achieved by strengthening the group's capabilities in drug development and manufacturing services in tandem with expanding its presence across the global pharmaceutical supply chain ecosystem, while leveraging its high-quality drug distribution services to seek new opportunities in the domestic drug and healthcare product markets. Specifically, Bora Health will continue to focus on the consumer healthcare market while Union Pharmaceutical will specialize in prescription drugs. Bora's continued accelerated growth has made brand reorganization an essential part of its long-term development strategy. With the organizational restructuring, Bora aims to integrate and expand its distribution and marketing services with a focus on prescription and OTC drugs and consumer healthcare products in a move to further its growth while creating more social and economic benefits through its brands.<br />Bora also disclosed that group chairman Bobby Sheng will lead Bora Health as chairman. The move to have the CDMO and distribution businesses each operate independently will further boost their growth in the markets they are engaged in. Additionally, by leveraging Bora's strong brand awareness and competitive CDMO services, Bora Health expects to enhance its distribution capabilities in world markets and deliver added value backed by brand consistency.</p>

READ NEXT

我們非常榮幸地宣布,享譽盛名的藝人陳美鳳女士已正式成為日本SSP藥廠旗下健康品牌愛斯飛特(DXB群的代言人。愛斯飛特是一家致力於提供高品質保健藥品的知名日本品牌,我們誠摯地歡迎陳美鳳女士加入我們的大家庭。

 

陳美鳳女士不僅是一位傑出的主持人、演員和歌手,更是一個充滿活力和熱情的健康生活倡導者。她的精湛演技和對健康生活的堅持讓她成為許多人的榜樣和靈感來源。陳美鳳女士的獨特風格與愛斯飛特品牌價值觀完美契合,我們深信她將為品牌注入新的活力和魅力。

 

作為愛斯飛特的代言人,陳美鳳女士將與我們共同致力於倡導健康活力的生活方式。她將積極參與品牌活動,推廣我們的產品,並與廣大消費者分享她對保健生活的熱情和經驗。

 

我們相信,陳美鳳女士的加入將進一步提升愛斯飛特在市場上的知名度和影響力。我們期待與她攜手合作,共同探索更多將健康與時尚相結合的可能性,為消費者帶來更多價值和良好生活品質。

 

最後,我們衷心感謝所有支持愛斯飛特品牌的消費者和合作伙伴。我們將繼續努力,不斷為您們提供更好的健康生活。

 

愛斯飛特關心您